A NEW GENERATION OF IMMUNO-ONCOLOGY

Eradicate cancer with next-generation immunotherapies

Next-generation immune-activating medicines against solid tumors, designed with our lab-in-the-loop AI platform.

THE SCIENCE

Harnessing the natural precision of T-cells.

Human T-cells use T-cell receptors (TCRs) to identify highly specific signs of disease that are present on sick cells and absent on healthy cells.

This natural phenomenon can be harnessed for the development of TCR-based medicines to eradicate solid tumors. However, safe, high-affinity TCRs against cancer targets are rare and hard to identify using traditional wet-lab methods.

Exogene combines generative AI with high-throughput TCR screening in the lab to design effective, safe and developable TCR-based medicines.

OUR DISCOVERY PLATFORM

Generate. Select. Test.

Our generative AI platform mines the TCR sequence space to discover novel, high-affinity and high-specificity candidates against targets shared across patients and tumor types.

A key data-generation advantage is our full-length TCR yeast display platform, which enables high-throughput experimental validation of AI predictions (lab-in-the-loop). The data feeds back into the models, creating an active learning loop that continuously improves prediction and design.

OUR TEAM

Built at the intersection of AI and immuno-oncology.

Our multidisciplinary team brings together computational biology, machine learning, protein science and therapeutic development.

CORE TEAM

team

Federico is a computational biologist with deep expertise in mathematical modelling and molecular biophysics. He holds a PhD in Molecular and Computational Oncology from the University of Oxford and has previously worked at the World Health Organization assessing cancer prevention strategies.

Federico Paoletti

CEO & Co-Founder

team

Andrea is an experienced machine learning scientist. He holds a PhD in Bio-Inspired Computation and has several years of experience building AI. He previously led the ML team at Portent.io (acquired by Yougov) and has worked at the European Space Agency, Honda Research Institute and Vodafone.

Andrea Mambrini

CTO & Co-Founder

team

Sebastian was the scientific mastermind behind the T cell engager programmes at Immatics (NASDAQ: IMTX). He spearheaded IMA401 and IMA402 from discovery all the way to first-in-human clinical trials, and unlocked the $150M upfront deal with BMS. Sebastian brings key scientific and commercial experience to help us develop and advance our assets towards the clinic.

Sebastian Bunk

Head of Pre-clinical Development

team

Muhammad holds a PhD in Mathematical Biology and Biophysical Chemistry from the University of Warwick. Over the last decade, he has worked on a broad range of protein engineering and structural biology projects at the interface of Physics, Chemistry and Biology. Prior to joining Exogene, he had been working on developing novel methods for the study and diagnostics of the SARS-CoV-2 virus.

Muhammad Hasan

Senior Director of R&D

team

Giovanni is a seasoned computational biologist with 6+ years experience in molecular dynamics and machine learning applied to TCR discovery and engineering from his time at Ardigen. Giovanni holds a PhD in Computer Science from the Polish Academy of Sciences.

Giovanni Mazzocco

Senior Computational Biologist

team

Jan-Gert is a protein biochemist with a PhD in Biology from the University of York. He previously worked at Memorial Sloan Kettering Cancer Center (MSKCC) developing in vitro assays to study how the DNA replication machinery deals with obstacles such as DNA damage and protein roadblocks to maintain genome integrity.

Jan-Gert Brüning

Principal Scientist

team

Alex is an experienced machine learning expert specialising in AI for biomedical research. At Ardigen, he served as a SCRUM master and developed models to predict peptide-HLA and TCR-pHLA binding. During his PhD at the Warsaw University of Technology, he focused on in-silico modelling of antigen recognition using machine learning.

Alexander Myronov

Senior Machine Learning Scientist

team

James is a project and operations manager with a strong background in tech start-ups. He previously helped scale high-throughput PCR testing operations at Oncologica and led projects to commercialise novel biomaterials at Xampla. James holds an MSci in Natural Sciences from the University of Bath.

James Ravenscroft

Senior Operations Manager

team

Ryan is an experienced machine learning scientist with a PhD in Chemistry from Cornell University. He joined Exogene from the machine learning group at Bayer and his recent work there was published at ICML. He previously worked at Intel, and in his spare time he participates in machine learning competitions.

Ryan Henderson

Senior Machine Learning Scientist

team

Foram is a cell biologist and immunologist with over five years of experience in oncology and immunotherapy. She earned her PhD from the University of Plymouth and has since contributed to cutting-edge research at Scancell, where she played a pivotal role in advancing bispecific T-cell engager programs through both in vitro and in vivo preclinical development.

Foram Dave

Senior Scientist

team

Jose Enrique holds a PhD in Pharmacology from the University of Cambridge. His doctoral research focused on the selection and characterisation of functional antibodies or nanobodies targeting challenging neuronal ion channels. Through his prior work, he has acquired significant experience in molecular biology, protein engineering, structural biology, and yeast display technology.

Jose Enrique Gonzalez-Prada

Research Scientist

team

Anthony is a molecular cell biologist with a PhD in Cellular Microbiology from the University of Cambridge. Whilst working in Academia he specialised in Host-Pathogen Interactions with a decade of research dedicated to the molecular mechanisms of bacterial entry. He recently transitioned into industry using his skills in cell engineering and assay development to characterise novel T-cell engagers.

Anthony Davidson

Senior Research Scientist

ADVISORY BOARD

team

Ricardo is a world expert in wet-lab methods for high-throughput screening of TCR-target pairs. He is a Principal Investigator at the University of Oxford and he has published in high-profile journals such as Nature Immunology, Cell and PNAS.

Ricardo Fernandes

Scientific Advisor

team

Alasdair has extensive experience negotiating and managing AI-driven co-development partnerships in the biopharmaceutical industry. He is a Founding Partner at Selvedge Venture and former director of deep-tech venture investments at Leaps by Bayer.

Alasdair Thong

Commercial Advisor

team

Livio is the co-founder of Vaxess Technologies, where he has pioneered a novel vaccine patch, raised over $80 million in funding, and collaborated with AstraZeneca on mRNA vaccine technologies. Before Vaxess, he worked at the United Nations, implementing silk production programs in Asia. Livio was named in the 2014 Forbes 30 under 30 list and holds a Masters in Public Policy from Harvard Kennedy School.

Livio Valenti

Commercial advisor

team

Prof. Paul Nathan is a leading medical oncologist at Mount Vernon Cancer Centre (UK) and a key opinion leader in kidney cancer. He played a pivotal role in leading the Phase 3 trial of Kimmtrak, a TCR-based bispecific T-cell engager therapy for uveal melanoma, which ultimately secured FDA approval.

Paul Nathan

Clinical Advisor

Partners

© 2026 Exogene. All rights reserved.
Wood Centre for Innovation, Stansfeld Park, Quarry Road, Headington, Oxford, OX3 8SB
Company registration no. 12293407